基于PI-RADS v2分型的前列腺癌风险分层:前瞻性研究的Meta分析
该Meta分析纳入13项前瞻性研究共4265名男性,评估PI-RADS v2各分类与临床显著前列腺癌检出率的关系。结果显示检出率随分类升高而单调增加:1-2类4%,3类17%,4类46%,5类75%。PI-RADS v2可用于风险分层,但4类仍存在局限。
要点
- PI-RADS v2各分类的临床显著前列腺癌检出率呈单调递增。
- 5类检出率高达75%,4类为46%,3类为17%,1-2类仅4%。
- 4类和1-2类的研究异质性显著,受人群选择和偏倚风险影响。
核心结论
- PI-RADS v2可用于对前列腺癌风险患者进行临床显著前列腺癌的风险分层,但4类的局限性仍然存在。
研究设计与样本
- 系统检索MEDLINE、EMBASE和Cochrane数据库,纳入13项前瞻性研究,共4265名男性,这些患者接受MRI靶向活检和/或系统活检(PI-RADS v2≥3)或系统活检(PI-RADS 1-2)。
- 采用随机效应模型计算各PI-RADS分类的临床显著前列腺癌和所有前列腺癌的合并检出率,并使用QUADAS-2评估偏倚风险,进行Meta回归分析探讨异质性来源。
主要发现
- 临床显著前列腺癌的合并检出率随PI-RADS v2分类单调增加:1-2类为4%(95%CI 2-8),3类为17%(95%CI 13-21),4类为46%(95%CI 38-55),5类为75%(95%CI 73-78)。
- 1-2类和4类的临床显著前列腺癌检出率存在显著研究异质性,受研究人群选择(是否仅为活检初治患者)和高偏倚风险研究的显著影响。
临床怎么用
- 可利用PI-RADS v2分类对可疑前列腺癌患者进行风险分层,辅助制定活检决策。
- 对PI-RADS 4类患者需注意其检出率的异质性,结合其他临床信息综合评估。
局限性
- 4类和1-2类的研究间异质性显著,可能影响合并检出率的可靠性。
- 部分研究存在高偏倚风险,可能影响结果解释。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The Prostate Imaging Reporting and Data System (PI-RADS) version 2 (v2) categorizes the likelihood of clinically significant prostate cancer on magnetic resonance imaging and determines the diagnostic pathway. We determined clinically significant prostate cancer and all prostate cancer detection rates in each PI-RADS v2 category. MATERIALS AND METHODS: MEDLINE®, EMBASE® and Cochrane databases were searched for prospective studies reporting the detection rates of clinically significant prostate cancer or all prostate cancer. Random effects models were used to determine pooled detection rates of clinically significant prostate cancer and all prostate cancer for each PI-RADS category. The risk of bias was assessed with the Quality Assessment of Diagnostic Accuracy Studies-2. Meta-regression analysis was performed to identify factors affecting study heterogeneity. RESULTS: Thirteen prospective studies including 4,265 men who underwent magnetic resonance imaging targeted biopsy and/or systematic biopsy for a PI-RADS v2 category 3 or greater, or systematic biopsy for PI-RADS 1-2 were included. The pooled detection rates of clinically significant prostate cancer monotonically increased for each PI-RADS v2 category, ie 4% (95% CI 2-8) for category 1-2, 17% (95% CI 13-21) for category 3, 46% (95% CI 38-55) for category 4 and 75% (95% CI 73-78) for category 5. Substantial study heterogeneity was noted in clinically significant prostate cancer detection rates for categories 1-2 and 4, which were significantly affected by study subject selection (biopsy naïve patients only or not) and studies with a high risk of bias. CONCLUSIONS: PI-RADS v2 can be useful for the stratification of the risk of clinically significant prostate cancer in patients at risk for prostate cancer but the limitations in category 4 still remain.
引用
- Park KJ, Choi SH, Lee JS, et al. Risk Stratification of Prostate Cancer According to PI-RADS® Version 2 Categories: Meta-Analysis for Prospective Studies. J Urol. 2020. PMID: 32716687. doi:10.1097/JU.0000000000001306
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。